Oppenheimer Upgrades Dyne Therapeutics to Outperform, Raises Price Target to $40
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Oppenheimer analyst Andreas Argyrides upgrades Dyne Therapeutics (NASDAQ:DYN) from Perform to Outperform and raises the price target from $11 to $40.
Oppenheimer analyst Andreas Argyrides upgrades Dyne Therapeutics (NASDAQ:DYN) from Perform to Outperform and raises the price target from $11 to $40.